AI 'Smart Family Doctor' support for people after CABG or PCI
"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients
We will test whether an AI-assisted smartphone 'Smart Family Doctor' program helps adults after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) better control blood pressure, blood sugar, and cholesterol.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 536 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | China National Center for Cardiovascular Diseases Government |
| Locations | 1 site (Ürümqi, Xinjiang) |
| Trial ID | NCT06615609 on ClinicalTrials.gov |
What this trial studies
This is a randomized controlled trial enrolling about 536 adults across multiple hospitals to compare an AI-assisted digital health management tool plus health manager support with usual care for secondary prevention after CABG or PCI. Eligible participants are adults (≥18) with prior CABG or PCI who also have hypertension, diabetes, and dyslipidemia and meet specified thresholds for blood pressure, HbA1c, or LDL-C. Participants will be randomized and followed to measure improvements in control rates of hypertension, diabetes, and dyslipidemia using the smartphone platform and manager-driven interventions. The primary outcomes are risk-factor control rates; data will be collected through the app, clinician visits, and routine labs.
Who should consider this trial
Good fit: Adults aged 18 or older who have had CABG or PCI, have hypertension, diabetes, and dyslipidemia meeting the study thresholds (elevated BP, HbA1c, or LDL-C), can use a smartphone, and can give informed consent are ideal candidates.
Not a fit: Patients with heart failure, severe arrhythmias, advanced organ failure, active cancer, pregnancy, cognitive or communication impairments, or those without a smartphone are unlikely to benefit or may be excluded.
Why it matters
Potential benefit: If successful, the program could improve blood pressure, glucose, and cholesterol control in post-CABG and post-PCI patients and lower their risk of future cardiac events.
How similar studies have performed: Previous smartphone and telehealth programs for cardiac secondary prevention have shown modest improvements in risk-factor control, but fully AI-driven 'family doctor' management approaches remain relatively new and less well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * History of CABG surgery or PCI with history of hypertension, diabetes, and dyslipidemia. * At least one of the following criteria is meet: * Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg * HbA1c no less than 7% * LDL-C no less than 1.4 mmol/L * Use of a smartphone. * Signed informed consent. Exclusion Criteria: * History of heart failure or severe arrhythmias. * Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency. * Pregnancy, lactation, or plans for pregnancy within the next year. * Cognitive, communication impairments, or limitations in daily activities.
Where this trial is running
Ürümqi, Xinjiang
- Xinjiang's First Affiliated Hospital of medical university — Ürümqi, Xinjiang, China (Recruiting)
Study contacts
- Principal investigator: Xin Yuan, PhD — Chinese Academy of Medical Sciences, Fuwai Hospital
- Study coordinator: Lihua Zhang Zhang, PhD
- Email: zhanglihua@fuwai.com
- Phone: 8601060866780
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.